For decades, drug developers have struggled to deliver therapies directly to the olfactory region of the nasal cavity, one of the more anatomically and physiologically complex targets in the human body. This region, nestled high within the upper nasal cavity, is home to the olfactory epithelium, the tissue within which the olfactory receptors reside, which are in part responsible for our sense of smell. Reaching it precisely is critical for treating certain conditions, such as post-viral hyposmia, but doing so with a medication that is both effective and safe remains one of the most underexplored frontiers in drug delivery science.
Treating post-viral hyposmia, a chronic condition characterized by the mild to severe loss of the sense of smell following a viral infection, is challenging. The condition affects tens of millions of people worldwide and has long been overlooked despite its significant impact on quality of life, nutritional health, and personal safety. When the sense of smell is lost, the sense of taste is diminished by as much as 80%, which means that two of the basic five senses are severely affected…